On Tuesday, the United States Supreme Court took a decisive step in the long-standing controversy over abortion post-Roe v. Wade by examining the regulatory framework surrounding mifepristone, a key drug in medical abortion protocols. This case, spotlighted for its profound implications on reproductive healthcare and the regulatory authority of the FDA, underscores the ongoing and contentious battle over abortion access in America.